PIK3CA and neoplasm: The third NGS analysis of tumor-normal DNA from a progressive bone biopsy taken under Infigratinib treatment revealed a different somatic single nucleotide variant (SNV) profile with an oncogenic, activating PIK3CA c.3140A>T, p.(His1047Leu) variant.